|Bid||128.9500 x 200|
|Ask||128.9500 x 200|
|Day's Range||128.8500 - 129.1000|
|52 Week Range||106.6900 - 129.1000|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.04%|
On September 13, 2017, Abbott Laboratories (ABT) announced the reimbursement approval of its Freestyle Libre system.
Dupixent combined with standard of care also showed 12%–15% improvement in FEV1 from baseline in asthma patients after 12 weeks of treatment compared to those treated with standard of care alone.
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...